Cargando…

Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results

BACKGROUND: Lymphoceles can result from disruption of lymphatic vessels after surgical procedures in areas with extensive lymphatic networks. Percutaneous catheter drainage with sclerotherapy can be performed for the treatment of lymphoceles. OK-432 has been used to treat benign cysts, such as lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Eiji, Ono, Yusuke, Yano, Hiroki, Kosai, Shinya, Nagai, Keisuke, Tanaka, Kaishu, Higashihara, Hiroki, Tomiyama, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584008/
https://www.ncbi.nlm.nih.gov/pubmed/36264442
http://dx.doi.org/10.1186/s42155-022-00332-z
_version_ 1784813186599354368
author Kashiwagi, Eiji
Ono, Yusuke
Yano, Hiroki
Kosai, Shinya
Nagai, Keisuke
Tanaka, Kaishu
Higashihara, Hiroki
Tomiyama, Noriyuki
author_facet Kashiwagi, Eiji
Ono, Yusuke
Yano, Hiroki
Kosai, Shinya
Nagai, Keisuke
Tanaka, Kaishu
Higashihara, Hiroki
Tomiyama, Noriyuki
author_sort Kashiwagi, Eiji
collection PubMed
description BACKGROUND: Lymphoceles can result from disruption of lymphatic vessels after surgical procedures in areas with extensive lymphatic networks. Percutaneous catheter drainage with sclerotherapy can be performed for the treatment of lymphoceles. OK-432 has been used to treat benign cysts, such as lymphangioma and ranula. Therefore, we aimed to report the efficacy and safety of sclerotherapy using OK-432 for postoperative lymphoceles. This study retrospectively analyzed 16 patients who underwent sclerotherapy using OK-432 for postoperative pelvic and para-aortic lymphoceles between April 1, 2012, and March 31, 2020. All the patients underwent percutaneous drainage before sclerotherapy. The indications for sclerotherapy were persistent drainage tube output of greater than 50 mL per day and recurrent lymphoceles after percutaneous drainage. If less than 20 mL per day was drained after sclerotherapy, the tube was removed. When the drainage tube output did not decrease to less than 20 mL per day after the first sclerotherapy, the second sclerotherapy was performed 1 week later. Technical success was defined as the completion of drainage and sclerotherapy procedures. Clinical success was defined as the resolution of the patient’s symptoms resulting from lymphoceles without surgical intervention. This study also evaluated the complications of sclerotherapy and their progress after sclerotherapy. RESULTS: The mean initial lymphocele size and drainage duration after sclerotherapy were 616 mL and 7.1 days, respectively. The technical success rate and clinical success rate were 100% and 93%, respectively. Thirteen patients were treated by one-session sclerotherapy and three patients were treated by two-session sclerotherapy. Minor complications (fever) were observed in eight patients (50%). A major complication (small bowel fistula) was observed in one patient (7%). No recurrence of lymphoceles was observed during the mean follow-up period of 17 months. CONCLUSION: Sclerotherapy with OK-432 is an effective therapeutic method for postoperative lymphoceles. Although most complications are minor, a small bowel fistula was observed in one patient.
format Online
Article
Text
id pubmed-9584008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95840082022-10-21 Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results Kashiwagi, Eiji Ono, Yusuke Yano, Hiroki Kosai, Shinya Nagai, Keisuke Tanaka, Kaishu Higashihara, Hiroki Tomiyama, Noriyuki CVIR Endovasc Original Article BACKGROUND: Lymphoceles can result from disruption of lymphatic vessels after surgical procedures in areas with extensive lymphatic networks. Percutaneous catheter drainage with sclerotherapy can be performed for the treatment of lymphoceles. OK-432 has been used to treat benign cysts, such as lymphangioma and ranula. Therefore, we aimed to report the efficacy and safety of sclerotherapy using OK-432 for postoperative lymphoceles. This study retrospectively analyzed 16 patients who underwent sclerotherapy using OK-432 for postoperative pelvic and para-aortic lymphoceles between April 1, 2012, and March 31, 2020. All the patients underwent percutaneous drainage before sclerotherapy. The indications for sclerotherapy were persistent drainage tube output of greater than 50 mL per day and recurrent lymphoceles after percutaneous drainage. If less than 20 mL per day was drained after sclerotherapy, the tube was removed. When the drainage tube output did not decrease to less than 20 mL per day after the first sclerotherapy, the second sclerotherapy was performed 1 week later. Technical success was defined as the completion of drainage and sclerotherapy procedures. Clinical success was defined as the resolution of the patient’s symptoms resulting from lymphoceles without surgical intervention. This study also evaluated the complications of sclerotherapy and their progress after sclerotherapy. RESULTS: The mean initial lymphocele size and drainage duration after sclerotherapy were 616 mL and 7.1 days, respectively. The technical success rate and clinical success rate were 100% and 93%, respectively. Thirteen patients were treated by one-session sclerotherapy and three patients were treated by two-session sclerotherapy. Minor complications (fever) were observed in eight patients (50%). A major complication (small bowel fistula) was observed in one patient (7%). No recurrence of lymphoceles was observed during the mean follow-up period of 17 months. CONCLUSION: Sclerotherapy with OK-432 is an effective therapeutic method for postoperative lymphoceles. Although most complications are minor, a small bowel fistula was observed in one patient. Springer International Publishing 2022-10-20 /pmc/articles/PMC9584008/ /pubmed/36264442 http://dx.doi.org/10.1186/s42155-022-00332-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kashiwagi, Eiji
Ono, Yusuke
Yano, Hiroki
Kosai, Shinya
Nagai, Keisuke
Tanaka, Kaishu
Higashihara, Hiroki
Tomiyama, Noriyuki
Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
title Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
title_full Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
title_fullStr Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
title_full_unstemmed Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
title_short Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
title_sort percutaneous sclerotherapy with ok-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584008/
https://www.ncbi.nlm.nih.gov/pubmed/36264442
http://dx.doi.org/10.1186/s42155-022-00332-z
work_keys_str_mv AT kashiwagieiji percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT onoyusuke percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT yanohiroki percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT kosaishinya percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT nagaikeisuke percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT tanakakaishu percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT higashiharahiroki percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults
AT tomiyamanoriyuki percutaneoussclerotherapywithok432forlymphoceleafterpelvicorparaaorticlymphadenectomypreliminaryresults